Cue Health Makes De Novo Submission to FDA for Full Clearance of its Cue® Flu Molecular Test

SAN DIEGO, Sept. 1, 2022 /PRNewswire/ — Cue Health (“Cue”) (Nasdaq: HLTH) today announced that it has made a de novo submission to the U.S. Food and Drug Administration (FDA) for full clearance of the Cue® Flu Molecular Test for at-home and point-of-care (POC) use. There are currently no…

Click here to view original post